Gyre Therapeutics Q1 net income $3.7M, revenue $22.1M; reaffirms FY2025 guidance $118–128M

GYRE THERAPEUTICS, INC.

2025-Q1 EPS reported $0.00 revenue$22,058,000

Net income $3.7M ($0.03 basic EPS) vs $9.9M in Q1 2024; revenue $22.1M, down 19% due to ETUARY decline from prior year one-time campaign.
FY2025 revenue guidance reiterated at $118–128M (2024: $105.8M); commercial launches of nintedanib (May 2025) and avatrombopag (March 2025) expected to drive H2 growth.
Phase 3 Hydronidone trial for CHB liver fibrosis completed data lock; topline results expected Q2 2025. IND approved for pirfenidone for radiation-induced lung injury.
Non-GAAP adjusted net income $2.9M vs $8.2M; cash $51.3M as of March 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.